Loading...
01/10 16:34
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary presents mixed signals: strong financial results with revenue and EPS growth, but concerns over China tariffs and paused orders. The Q&A reveals management's uncertainty about the tariff impact and delayed orders, but they express confidence in temporary revenue reductions. The strategic plan highlights a significant cargo inspection order and growth opportunities, yet geopolitical risks loom. Overall, the positive financial performance is offset by uncertainties in China, leading to a neutral stock price prediction.
Total Revenue $213 million, up 3% year-over-year, driven by a 3% increase in both Medical and Industrial segments.
Non-GAAP Gross Margin 36%, up from 33% year-over-year, due to increased volume, favorable product sales mix, and productivity gains.
Adjusted EBITDA $34 million, up from $25 million year-over-year.
Non-GAAP EPS $0.26, up from $0.16 year-over-year.
Cash from Operations $17 million, driven by improved profitability and solid working capital management.
Cash, Cash Equivalents, and Marketable Securities $226 million, up $36 million year-over-year.
Operating Income $26 million, an increase of $13 million year-over-year.
Net Earnings $12 million, compared to $7 million in the year-ago quarter.
Gross Debt Outstanding $570 million.
Net Debt $219 million, after accounting for cash and marketable securities.
R&D Spending $22 million, a decrease of $1 million year-over-year.
SG&A Expense $29 million, a decrease of $3 million year-over-year.
Operating Expenses $51 million, a decrease of $3 million year-over-year.
Operating Margin 12%, up from 6% year-over-year.
Days Sales Outstanding 62 days, a decrease of 6 days.
Days of Inventory 190 days, a decrease of 19 days.
Days Payable 47 days, a decrease of 2 days.
Trailing 12-month Adjusted EBITDA $103 million.
Net Debt Leverage Ratio Approximately 2.1 times adjusted EBITDA.
New Product Launch: Canon Medical Systems introduced a new CT system called Aquilion Rise, which uses a CT tube made by Varex. This system can image patients in multiple positions, enhancing lesion detection.
Photon Counting Technology: Varex is actively engaged with large imaging OEMs to integrate photon counting detector technology into next-generation CT systems, with two OEMs in R&D and others evaluating the technology.
New Product Offering: Varex showcased its THOR product, a linear array detector for high-speed 3D imaging and inspection, at the Control Trade Show in Stuttgart, Germany.
Market Expansion: Sales in the APAC region increased by 8%, primarily due to increased sales in China, which constituted 15% of total sales.
New Orders: Varex announced a new order worth $25 million for cargo inspection systems from an international customer, in addition to $14 million of orders from other international customers.
Operational Efficiency: Gross margin improved to 36%, up from 33% year-over-year, due to increased volume, favorable product sales mix, and productivity gains.
Cash Flow Management: Cash from operations was $17 million, driven by improved profitability and solid working capital management.
Strategic Shift: Varex is implementing options to mitigate the impact of tariffs, including localizing manufacturing and redirecting material purchases to lower tariff countries.
Debt Management Strategy: Varex plans to repay $200 million of convertible notes upon maturity in June, reducing overall debt burden and simplifying capital structure.
Tariff Impact on Sales: The 125% tariff imposed by China on US products is expected to negatively impact sales by about $20 million in the third quarter due to a pause in purchases by some China-based customers.
Cost of Goods Sold: Raw materials and components sourced from global suppliers can include tariffs ranging from 10% to 145%. Materials imported into the US from China represent approximately 3% of total cost of goods sold.
Gross Margin Impact: The impact on gross margins, net of mitigation efforts, is expected to be in the 150 to 200 basis point range on a go-forward basis due to increased costs from tariffs.
Regulatory Investigations: The China Ministry of Commerce has initiated investigations into medical products imported into China, which could affect Varex's competitiveness and sales.
Economic Factors: The current geopolitical situation and tariff environment are dynamic and could lead to further adjustments in Varex's mitigation plans.
Cash Management: Cash generation was strong with cash from operations of $17 million in the quarter, ending with $226 million in cash, cash equivalents, and marketable securities.
Debt Repayment: Plan to use restricted cash and other cash on hand to repay the outstanding principal of $200 million convertible notes upon maturity in June.
Product Development: Continued engagement with large imaging OEMs to integrate photon counting detector technology in next generation CT systems.
New Orders: Announced a new order worth $25 million for cargo inspection systems, in addition to $14 million from previous quarter.
Mitigation Strategies: Implementing options to reduce tariff impacts, including localizing manufacturing and redirecting material purchases.
Revenue Guidance: Expected revenues for Q3 between $180 million and $200 million, assuming $10 million sales in China.
EPS Guidance: Non-GAAP earnings per diluted share expected between -$0.05 loss and $0.10 profit.
Gross Margin Guidance: Non-GAAP gross margin expected between 32% and 33%, including 150 basis points impact from tariff-related costs.
Operating Expenses Guidance: Non-GAAP operating expenses expected to be approximately $51 million.
Tax Rate Guidance: Tax rate expected to be about 25% for Q3.
Convertible Notes Repayment: Varex Imaging Corporation plans to repay the outstanding principal of $200 million of convertible notes upon maturity in June.
Cash and Cash Equivalents: The company ended the quarter with $226 million in cash, cash equivalents, and marketable securities.
Restricted Cash: Additionally, Varex has $125 million of restricted cash raised from a senior secured debt offering, earmarked for paying down convertible notes.
The earnings call presents a mixed picture: strong financial performance with record high revenue and improved profitability, but concerns about cash reduction and uncertain guidance. The Q&A indicates solid demand and growth prospects, but management's lack of specific guidance and avoidance of details raises uncertainty. Without clear guidance, the market may react cautiously, resulting in a neutral stock price movement.
The earnings call summary presents a mixed picture. Financial performance is stable with strong cash management and expected revenue growth, but gross margins are impacted by tariffs. Product development in photon counting is promising but lacks immediate commercialization. Market strategy shows steady demand in China and a strong cargo systems pipeline, but lacks clarity in future guidance. Shareholder returns and debt repayment plans are positive, yet overall, the lack of clear guidance and tariff impacts balance the sentiment to neutral.
The earnings call summary presents mixed signals: strong financial results with revenue and EPS growth, but concerns over China tariffs and paused orders. The Q&A reveals management's uncertainty about the tariff impact and delayed orders, but they express confidence in temporary revenue reductions. The strategic plan highlights a significant cargo inspection order and growth opportunities, yet geopolitical risks loom. Overall, the positive financial performance is offset by uncertainties in China, leading to a neutral stock price prediction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
